News Article

Global biopharmaceutical company AstraZeneca has announced a $50 billion investment in the United States by 2030 to expand its pharmaceutical manufacturing and R&D footprint.

The initiative, unveiled on July 22, 2025, includes a proposed multi-billion-dollar manufacturing facility in Virginia focused on chronic disease treatments such as oral GLP-1s, baxdrostat for hypertension, and PCSK9 inhibitors, which will be the company’s largest single-site investment globally. This expansion aims to secure the U.S. market, where the company generates over 40% of its sales, and supports its goal of achieving $80 billion in annual revenue by 2030, with half of that revenue projected to come from the U.S..

The investment is also part of broader U.S. projects, including R&D expansion in Gaithersburg, Maryland, a new research hub in Massachusetts, and next-generation cell therapy facilities in Maryland and California, alongside manufacturing expansions in Indiana and Texas. AstraZeneca’s CEO, Pascal Soriot, emphasized that the move is a “business decision” to strengthen domestic supply chains and avoid potential tariffs, though the company stated it was not motivated solely by political pressures. The new facilities will leverage artificial intelligence, automation, and data analytics to optimize production.

Analysts note the investment reflects growing industry efforts to mitigate risks from Trump’s proposed 200% pharmaceutical tariffs and regulatory uncertainties, with AstraZeneca joining peers like Roche and Eli Lilly in scaling U.S. operations. The company reaffirmed its high-single-digit revenue growth guidance for the year, with core EPS growth projected at low double digits.